SCHEMBL1963069

SCHEMBL1963069

N#CCC(=O)NC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9129124 0.92 KMT2A (0.71)
SCHEMBL9129119 0.92 KMT2A (0.71)
SCHEMBL6322623 0.91 KMT2A (0.70)
SCHEMBL15797043 0.91 KMT2A (0.70)
SCHEMBL14654974 0.90 KMT2A (0.69)
SCHEMBL6321675 0.90 KMT2A (0.68)
SCHEMBL1403047 0.90 KMT2A (0.68)
SCHEMBL22436470 0.86 KMT2A (0.64)
SCHEMBL14652034 0.86 KMT2A (0.63)
SCHEMBL6324524 0.86 KMT2A (0.63)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885337-B1 FTO INHIBITORS NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2025-01-15 EP disclosed
CN-118946553-A SARM1 inhibitor compound, pharmaceutical composition comprising the same, and preparation method and use thereof 深圳众格生物科技有限公司 2024-11-12 CN disclosed
WO-2023193809-A1 SARM1 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USES THEREOF 深圳众格生物科技有限公司 2023-10-12 WO disclosed
US-20230142913-A1 TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2023-05-11 US disclosed
CN-107922316-B FTO inhibitors 北京生命科学研究所 2022-04-08 CN disclosed
CN-113801187-A Preparation and application of Michael acceptor type main protease inhibitor targeting novel coronavirus 南开大学 2021-12-17 CN disclosed
EP-3885337-A1 FTO INHIBITORS National Institute Of Biological Sciences, Beijing (CN) 2021-09-29 EP disclosed
EP-3885337-A1 FTO INHIBITORS National Institute Of Biological Sciences, Beijing (CN) 2021-09-29 EP disclosed
US-20210238127-A1 FTO Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-05 US disclosed
US-20210238127-A1 FTO Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-05 US disclosed
WO-2007073283-A1 SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS ASTRAZENECA AB (SE) 2007-06-28 WO disclosed
US-20070142328-A1 Compounds and Uses Thereof ASTRAZENECA AB (SE) 2007-06-21 US disclosed
US-20070142382-A1 Compounds and Uses Thereof ASTRAZENECA AB (SE) 2007-06-21 US disclosed
US-20070049757-A1 Methods for the synthesis of substituted amino uracils ADENOSINE THERAPEUTICS, LLC 2007-03-01 US disclosed
US-20070049757-A1 Methods for the synthesis of substituted amino uracils ADENOSINE THERAPEUTICS, LLC 2007-03-01 US disclosed
US-20070049757-A1 Methods for the synthesis of substituted amino uracils ADENOSINE THERAPEUTICS, LLC 2007-03-01 US disclosed
EP-1565461-A2 ANTIBACTERIAL SUBSTITUTED CYANOMETHYL(ENE)PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Patel, Mahesh V. (IN) 2005-08-24 EP disclosed
US-20040063954-A1 Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites WOCKHARDT LIMITED 2004-04-01 US disclosed
WO-2004007489-A2 ANTIBACTERIAL SUBSTITUTED CYANOMETHYL (ENE) PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS OR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM WOCKHARDT LIMITED (IN) 2004-01-22 WO disclosed
US-4586954-A Arylacryl aliphatic amide herbicidal compounds and methods of use STAUFFER CHEMICAL CO. (US) 1986-05-06 US disclosed